Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) has been assigned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price target among brokerages that have covered the stock in the last year is $31.75.
YMAB has been the subject of a number of recent research reports. HC Wainwright initiated coverage on shares of Y-mAbs Therapeutics in a research note on Monday, April 1st. They issued a “buy” rating and a $36.00 price objective for the company. Zacks Investment Research raised shares of Y-mAbs Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, March 15th.
Shares of NASDAQ:YMAB opened at $20.92 on Tuesday. Y-mAbs Therapeutics has a 52 week low of $15.17 and a 52 week high of $31.00. The firm has a market capitalization of $715.34 million and a price-to-earnings ratio of -13.95. The company has a debt-to-equity ratio of 0.02, a current ratio of 13.30 and a quick ratio of 13.30.
In other news, insider Thomas Gad sold 6,000 shares of the firm’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $20.61, for a total value of $123,660.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.
Several institutional investors have recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in shares of Y-mAbs Therapeutics by 32.2% in the 4th quarter. FMR LLC now owns 1,626,642 shares of the company’s stock worth $33,086,000 after acquiring an additional 396,000 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Y-mAbs Therapeutics by 20.9% in the 4th quarter. Millennium Management LLC now owns 386,919 shares of the company’s stock worth $7,870,000 after acquiring an additional 67,013 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of Y-mAbs Therapeutics by 8.0% in the 1st quarter. BlackRock Inc. now owns 369,159 shares of the company’s stock worth $9,676,000 after acquiring an additional 27,328 shares during the last quarter. Vanguard Group Inc bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $2,260,000. Finally, Vanguard Group Inc. bought a new stake in shares of Y-mAbs Therapeutics in the 3rd quarter worth about $2,260,000. Hedge funds and other institutional investors own 25.36% of the company’s stock.
Y-mAbs Therapeutics Company Profile
Y-mAbs Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody-based therapeutic products for the treatment cancer in the United States. It is developing naxitamab for the treatment of pediatric patients with relapsed or refractory, high-risk neuroblastoma, as well as other GD2 positive tumors; and omburtamab for the treatment of pediatric patients with central nervous system, leptomeningeal metastases, desmoplastic small round cell tumors, diffuse intrinsic pontine glioma, and other B7-H3 positive tumors.
Further Reading: What are the qualifications of a portfolio manager?
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.